“Payers and health-technology assessment agencies at multiple levels of healthcare systems have a growing influence on market-access conditions for medicines in Europe,” according to the new syndicated report’s executive summary. “The barriers to market access are increasing as health systems address the challenges of sustainability in the face of global trends such as population ageing.”
Some of the questions explored in the report are:
- What EU-wide harmonization is underway and what impact is it likely to have?
- How is the European market-access landscape likely to evolve over the next five years?
- Which drugs/disease areas are of most concern for payers and why?